PPARδ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
== Further reading == Collins R (2017). "Lowering Restrictions on Performance Enhancing Drugs in Elite Sports". Inquiries Journal. 9 (3). Retrieved 7 July 2017. Franke WW, Berendonk B (July 1997). "Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government". Clinical Chemistry. 43 (7): 1262–79. doi:10.1093/clinchem/43.7.1262. PMID 9216474. Mottram, David (2005); Drugs in Sport, Routledge. ISBN 978-0-415-37564-1. Murray, Thomas H. (2008); "Sports Enhancement", in From Birth to Death and Bench to Clinic: The Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns. Pope J, Harrison G, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S (2014). "Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement". Endocrine Reviews. 35 (3): 341–375. doi:10.1210/er.2013-1058. PMC 4026349. PMID 24423981. Waddington and Smith (2008); An Introduction to Drugs in Sport, Routledge. ISBN 978-0-415-43125-5. Collins R (2017). "Lowering Restrictions on Performance Enhancing Drugs in Elite Sports". Inquiries Journal. 9 (3). Retrieved 7 July 2017. Toby M (2024). The History of Performance-Enhancing Drugs In Thoroughbred Racing. University of Kentucky Press. ISBN 9780813197975.
=== Initial stranding === The carcass was first spotted on the evening of November 30, 1896, by two young boys, Herbert Coles and Dunham Coretter, while bicycling along Anastasia Island. The enormous mass was half buried in the sand, having sunk under its immense weight. The two boys thought the carcass was the remains of a beached whale, as a similar stranding had occurred two years earlier near the mouth of the Matanzas River, located several miles to the south of St. Augustine (see map). The two boys returned to St. Augustine the same day and reported their discovery to a local physician, Dr. DeWitt Webb. Webb, who was the founder of the St. Augustine Historical Society and Institute of Science, came to the beach the following day, December 1, to examine the remains. He would be the only known person of an academic background to see the specimen in situ. His first impression was that it was the remains of an animal, very mutilated, and in an advanced state of decomposition. The carcass was very pale pink, almost white, in colour, with a silver reflection in the sunlight. It was composed of a rubbery substance of a very hard consistency, such that it could only be cut with great difficulty. The part of the carcass that was visible measured 18 feet (approx. 6 meters) in length and 7 feet (approx. 2+1⁄2 meters) in width. Webb estimated its weight at nearly 5 tons, if not more. He believed it was the remains of a giant octopus, as it appeared to have the stumps of four arms, with another arm buried nearby.
== Services == The Instituto Universitario de Restauración del Patrimonio is divided into two areas: the area of intervention in the Pictorial and Sculptural Heritage and the area of intervention in the Architectural Heritage, and a Training and Dissemination area. The area of intervention in the pictorial and sculptural heritage operates in both basic research and applied research in seeking to acquire new knowledge to develop new products, techniques, processes, methods and systems that improve existing ones. The area of intervention in the Pictorial and Sculptural Heritage consist in restoration workshops:
Sources: en.wikipedia.org
== Structure == Moroidin, a bicyclic octapeptide, has been isolated from Dendrocnide moroides (also called Laportea moroides) and Celosia argentea. The structure of moroidin was confirmed in 2004 by X-ray crystallography. It contains two unusual crosslinks, one between leucine and tryptophan and the other between tryptophan and histidine. These linkages are also present in an analogous family of compounds, the celogentins.
Ullrich congenital muscular dystrophy (UCMD) is a form of congenital muscular dystrophy. There are two forms: UCMD1 and UCMD2. UCMD1 is associated with variants of type VI collagen, while UCMD2 is associated with variants of type XII collagen. UCMD is commonly associated with contractures, joint laxity, muscle weakness, and respiratory problems, though cardiac issues are not associated with this type of CMD. It is named after Otto Ullrich, who is also known for the Ullrich-Turner syndrome.
== Dietary recommendations == The Food and Nutrition Board (FNB) of the U.S. Institute of Medicine set Recommended Dietary Allowances (RDAs) for essential amino acids in 2002. For phenylalanine plus tyrosine, for adults 19 years and older, 33 mg/kg body weight/day. In 2005, the DRI was set to 27 mg/kg per day (with no tyrosine), the FAO/WHO/UNU recommendation of 2007 is 25 mg/kg per day (with no tyrosine).
Sources: en.wikipedia.org
1990 Thomas Jefferson Award from the University of Virginia Distinguished Alumni Award from the University of Minnesota Medical Alumni Association (2005) James D. Mills Award from the American College of Emergency Physicians (2008) Solomon A. Berson Award in Health Sciences from the New York University School of Medicine (2011).
=== Lack of infrastructure and transparency === The absence of modern infrastructure and transparent regulatory oversight allows corrupt practices to flourish. Inefficient transportation and storage systems result in spoilage and loss, reducing the effective supply of food. Additionally, the government's lack of proper market monitoring mechanisms enables these inefficiencies and manipulations to persist unchecked.
The beginning of Trump's second presidency is largely recognized as the one theorized by political strategist Steve Bannon during Trump's first presidency, here deployed by Stephen Miller. The strategy consists of "flood[ing] the zone of shit", with an impressive number of claims and executive orders with the intent to tire journalists, political opponents and judicial institutions. As such the latter can't react rapidly and appropriately enough, and it nips controversies in the bud because of the flood of information. The administration had already prepared diverse executive orders to allow the signing of 55 executive orders in 20 days, a frequency never before seen.
A birch is a thin-leaved deciduous hardwood tree of the genus Betula (), in the family Betulaceae, which also includes alders, hazels, and hornbeams. It is closely related to the beech-oak family Fagaceae. The genus Betula contains 30 to 60 known taxa of which 11 are on the IUCN 2011 Red List of Threatened Species. They are typically short-lived pioneer species and are widespread in the Northern Hemisphere, particularly in northern areas of temperate climates and in boreal climates. Birch wood is used for a wide range of purposes.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.